Drugs / ONO-8539
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01705275 | Jan 2013 → Mar 2014 | gastroesophageal reflux disease | Ono Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01707901 | Dec 2012 → Oct 2014 | gastroesophageal reflux disease | Ono Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00876421 | Apr 2009 → Apr 2010 | overactive bladder | Ono Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ONO-8539 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01705275 ↗ |
| Action | Inhibit | “Prostanoid EP1 receptor antagonist” CHEMBL3912251 ↗ |
| Modality | Small molecule | — CHEMBL3912251 ↗ |
| Target | PTGER1 | “Prostanoid EP1 receptor antagonist” CHEMBL3912251 ↗ |